| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $7.4M | -20.2% | -42.4% |
| SG&A Expense | $3.5M | -13.7% | -32.1% |
| Operating Income | -$11.0M | +18.2% | +39.4% |
| Net Income | -$8.5M | +19.5% | +45.4% |
| EPS (Basic) | -$0.15 | +21.1% | +46.4% |
| EPS (Diluted) | -$0.15 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $30.9M | +2.9% | +31.8% |
| Current Assets | $139.0M | -5.3% | +20.3% |
| Total Assets | $157.7M | -5.2% | +14.4% |
| Current Liabilities | $15.5M | -7.5% | -25.3% |
| Total Liabilities | $31.6M | -6.5% | -22.0% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $36.4M | — | — |
| Investing Cash Flow | -$42.0M | — | — |
| Financing Cash Flow | $50K | — | — |
| +46.4% |
| $126.2M |
| -4.9% |
| +29.5% |